Autonomic neuropathy, gastrointestinal motility, and inflammation in HIV
PI: [INVESTIGATOR_554655]-Papp
[STUDY_ID_REMOVED]
Document Date: July 1, 2016 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
1 
Revised 9/2/14 
Brief Summary of Research :  
HIV-infected patients commonly develop autonomic neuropathy (HIV-AN), which is a 
heterogeneous disorder characterized by [CONTACT_554676].  We hypothesize that the vagal component of HIV-AN contributes to chronic 
inflammation, both directly via loss of cholinergic activity, and indirectly via effects on the GI 
tract, and that these effects will be treatable using the acetylcholinesterase inhibitor 
pyridostigmine.  The autonomic nervous system controls the inflammatory response to 
lipopolysaccharide (LPS) via the cholinergic anti-inflammatory pathway.  This pathway is 
mediated by [CONTACT_554677], and is therefore likely impaired in HIV-AN with vagal dysfunction.  
Vagal dysfunction also causes slowed GI transit, which could exacerbate LPS-driven 
inflammation by [CONTACT_554678].  However, the anti-inflammatory impact of 
cholinergic pathways is almost completely unstudied in HIV, despi[INVESTIGATOR_554656]. Therefore, in this exploratory pi[INVESTIGATOR_2268], we seek to establish 
associations between vagal dysfunction, GI motility and inflammation in virally suppressed, 
CART-treated individuals with HIV-AN.  
Specific Aim 1:  To determine whether vagal dysfunction is associated with immune activation in 
CART-treated participants with HIV-AN, and if so to estimate the extent to which this association 
is mediated by [CONTACT_554679] (i.e. slowed motility, bacterial overgrowth, microbial translocation) 
versus direct effects of vagal dysfunction.  
Specific Aim 2: In a subset of participants who have both vagal and GI dysfunction, to investigate 
whether 8 weeks of pyridostigmine: a) reduces immune activation, and b) improves GI motility; 
and if the immune effect depends on the GI effect.  
To achieve these aims, participants with HIV-AN and GI symptoms will be assessed for: vagal 
dysfunction (heart rate variability); GI dysmotility (gastric emptying scintigraphy); small intestinal 
bacterial overgrowth (breath testing); microbial translocation (LPS and sCD14); and immune 
activation (IL-6 and CRP).  Participants meeting threshold criteria for both vagal and GI 
dysfunction will then be treated with pyridostigmine for 8 weeks, after which GI and immune 
measures will be reassessed.   
1) Objectives 
Specific Aim 1:  To determine whether vagal dysfunction is associated with immune activation in 
HIV-infected participants treated with combination antiretroviral therapy (CART), and if so to 
estimate the extent to which this association is mediated by [CONTACT_554679] (i.e. slowed motility, 
bacterial overgrowth, microbial translocation) versus direct effects of vagal dysfunction.  
Specific Aim 2: In a subset of participants who have both vagal and GI dysfunction, to investigate 
whether 8 weeks of pyridostigmine: a) reduces immune activation, and b) improves GI motility; 
and if both effects are present to determine whether the immune effect depends on the GI effect.  
 
3URWRFRO1DPH $XWRQRPLFQHXURSDWK\JDVWURLQWHVWL QDOPRWLOLW\DQGLQIOD[COMPANY_003]WL RQ
LQ+,9
3ULQFLSDO,QYHVWLJDWRU -HVVLFD5RELQVRQ3DSS0'06
3ULPDU\&RQWDFW
1DPH&RQWDFW,QIR0DU\&DWKHULQH*HRUJH PDU\FDWKHULQHJHRUJH#PVVPHGX 

'DWH5HYLVHG 
6WXG\1XPEHU +6*&21,+ 


5HYLVHG
%DFNJURXQG

,QWKLVVWXG\ZHSURSRVHWRJHQHUDWHSUHOLPLQDU\HYLGHQFHWKDW WKH
YDJDOG\VIXQFWLRQWKDWRFFXU VDVSDUWRI+,9DVVRFLDWHG
DXWRQRPLFQHXURSDWK\+,9$1LVDVVRFLDWHGZLWKLPPXQHDFWLYDWLRQLQYLUDOO\VXSSUHVVHG&$57WUHDWHG+,9DFWLQJERWK 
GLUHFWO\YLDORVVRIFKROLQHUJLFDFWLYLW\DQGLQGLUHFWO\YLDH IIHFWV
RQWKH*,WUDFWDQGWKDWWKHVHHII HFWVZLOOEHWUHDWDEOHE\
LQFUHDVLQJWKHDYDLODELOLW\RI WKHQHXURWUDQVPLWWHUDFHW\OFKROL QH
$&K7KHVHDUHQRYHOK\S RWKHVHVWKDWKDYHQRWSUHYLRXVO\EHHQ 
WHVWHGDOWKRXJKWKHUHLVHYLGHQFHWRVXSSRUWHDFKLQGLYLGXDOFRPSRQHQWRIWKHP6KRXOGHYLGHQFHEHJDWKHUHGFRQVLVWHQWZLWKWKHVHK\SRWKHVHVLWZRXOGFRQVWLW XWHDILUVWVWHSLQLQYHVWLJD WLQJD
SRWHQWLDOO\WUHDWDEOHQRQYLUDOSDWKZD \VXEVHUYLQJFKURQLF
LPPXQHDFWLYDWLRQLQ&$57WUHDWHG+,9&KURQLFLPPXQHDFWLYDWLRQSOD\VDQLPSRUWDQWUROHLQWKHSURJUHVVLRQRI+,9W KHGHYHORSPHQWRIFRPRUELGLWLHVDQG
DFFHOHUDWHGDJLQJ
,QIOD[COMPANY_003]WRU\F\WRNLQHVDQGE LRPDUNHUVRIK\SHUFRDJXODELOLW\D UHHOHYDWHGLQ+,9
HYHQLQWKHVHWWLQJRIHIIHF WLYH&$57DQGDUH DVVRFLDWHGZLWK PRUELGLW\SDUWLFXODUO \FDUGLRYDVFXODU
GLVHDVHDQGPRUWDOLW\0LF URELDOWUDQVORFDWLRQIURPWKH*,WU DFWGXHWRGLVUXSWLRQRIWKHQRUPDOPXFRVDO
EDUULHULVDQLPSRUWDQWGULYHU RIWKLVLPPXQHDFWLYDWLRQ7RGDWHWKHUHKDVEHHQQRFRQVLGHUDWLRQRI
DXWRQRPLFIXQFWLRQLQPDLQWDLQL QJWKHLQWHJULW\RIWKLVEDUULHU LQ+,9HLWKHUWKURXJKHIIHFWVRQPRWLOLW\
RUYLDFKROLQHUJLFVWLPXODWLRQRILPPXQHFHOOV,QWKHIROORZL QJVXEVHFWLRQVZHZLOOSUHVHQWHYLGHQFHWR
VXSSRUWDVVRFLDWLRQVEHWZHHQDXWRQRP LFIXQFWLRQDQGLQSDUWLFX ODUYDJDOIXQFWLRQ*,IXQFWLRQDQG
LPPXQHDFWLYDWLRQDQGWKHLUVLJQLILFDQFHWRWKHSURSRVHGVWXG\ LQ+,9
+,9DXWRQRPLFQHXURSDWK\DQG*,HIIHFWV :HUHFHQWO\UHSRUWHGWKDW+,9 $1LVFRPPRQDQGW\SLFDOO\
RFFXUVDVSDUWRIDPRUHJHQHUDOL] HGQHXURSDWKLFSURFHVVWKDWL QFOXGHV+,9DVVRFLDWHGGLVWDOV\PPHWULF
SRO\QHXURSDWK\+,9'63:HGHWHUPLQHGWKLVE\SHUIRU PLQJDFRPSUHKHQVLYHDXWRQRPLF
DVVHVVPHQWRQ+,9LQIHFWHGLQGLYLGXDOVFRQVLVWLQJRIKHDUW UDWHUHVSRQVHWRGHHSEUHDWKLQJ9DOVDOYD
PDQHXYHUWLOWWDEOHWHVWLQJDQGTX DQWLWDWLYHVXGRPRWRUD[RQU HIOH[WHVWLQJ6XFKWHVWLQJLVFRQVLGHUHGWKH
GLDJQRVWLFJROGVWDQGDUGDQGFDQEHVX[COMPANY_003]UL]HGDVWKH&RPSRVL WH$XWRQRPLF6HYHULW\6FRU H
&$66DYDOLGDWHGVFRUH ZLWKVHQVLWLYLW\DQGVSHFLILFLW\!RUDVWKHPRGLILHG&$66P&$66
DFORVHO\UHODWHGVFRUHWKD WZHUHFHQWO\GHYHORSHGIRUXVHLQ+ ,9%RWKWKH&$66DQGWKHP&$66
FRQWDLQWKUHHVXEVFRUHVUHIOHFWLQ JGLIIHUHQWDXWRQRPLFIXQFWLR QVVXGRPRWRUFKROLQHUJLFV\PSDWKHWLF
LQQHUYDWLRQRIVZHDWJODQGVYDJD OFDUGLDFFKROLQHUJLFSDUDV\ PSDWKHWLFLQQHUYDWLRQDQGV\PSDWKHWLF
QRUDGUHQHUJLFV\PSDWKHWLFLQQHU YDWLRQRIYDVFXODWXUH:HIRX QGWKDWRISDUWLFLSDQWVPHWWKH
GHILQLWLRQIRU+,9$1&$66¬ïEXWWKDWWKHGHILFLWVZHUHKH WHURJHQHRXV)RUH [DPSOHDOWKRXJK
QHDUO\KDGV\PSDWKHWLFGHILFLWVHLWKHUYDVFXODURUVXGRPRW RURQO\KDGYDJD OGHILFLWV7KHVH
ILQGLQJVVXJJHVWWKDW+,9$1LVYDULDEOHLQLWVDQDWRPLFGLVWUL EXWLRQDQGWKHUHIRUHOL NHO\WREHYDULDEOHLQ
LWVFOLQLFDOPDQLIHVWDWLRQV6\PSWRPVSRWHQWLDOO\DWWULEXWDEOH WR+,9$1ZHUHRYHUDOOQRQVSHFLILF
LQFOXGLQJRUWKRVWDWLFGL]]LQHVVRUIDLQWLQJGU\H\HVRUPRXWK XULQDU\DQGVH[XDOG\VIXQFWLRQFKDQJHVLQ

 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
3 
Revised 9/2/14 
sweating, and nausea.  The only symptom that was significantly associated with HIV-AN was 
constipation (p<.001), suggesting possible slowed GI transit time . 
 
The end-organ effects of HIV-AN are currently unknown, although in the broader field of autonomic 
dysfunction, GI dysmotility is a well-recognized effect,11-14 which is characterized clinically by [CONTACT_554680], vomiting or bloating especially after meals, and constipation and/or diarrhea.15,[ADDRESS_728528].30  
 
Autonomic neuropathy, cholinergic anti-inflammatory pathways, and pyridostigmine.  Outside of the 
realm of HIV research, autonomic effects on inflammation, particularly in response to lipopolysaccharide 
(LPS), have been extensively studied and dubbed the ‚Äúcholinergic anti-inflammatory reflex.‚Äù[ADDRESS_728529].33  In 
humans, it has been observed that trauma patients undergoing vagotomy experience greater rates of 
sepsis, ulcers, and mortality when compared to those without vagotomy.34  Additionally, in septic 
humans, decreased heart rate variability, a marker of vagal dysfunction, is correlated with inflammatory 
markers (e.g. IL-6, CRP) and poor outcomes including progression to shock and death.35,36  
The vagus nerve regulates inflammation via release of ACh, which can bind the nicotinic ACh receptor 
subunit Œ±7 (Œ±7nAChR) present on monocytes, macrophages, B cells, T cells and dendritic cells.  In the GI 
tract, vagal action on macrophages and dendritic cells is thought to be mediated through stimulation of the 
myenteric plexuses, and subsequent release of ACh to immune effectors in the muscularis.37,38  In the 
spleen, vagal stimulation of the celiac ganglion may result in adrenergic stimulation of T cells, a subset of 
which release ACh to stimulate macrophages.31  In both gut wall and circulating monocytes/macrophages, 
the effect of Œ±7nAChR activation is to induce intracellular signaling which suppresses the transcription of 
pro-inflammatory cytokines and mediators, dependent upon upregulation of heme oxygenase 1 (HO-1).39  
In dendritic cells and monocytes/macrophages, activation of Œ±7nAChR also inhibits secretion of high 
mobility group box 1 (HMGB1), an alarmin essential to the innate immune reponse.[ADDRESS_728530] been in murine models, there is experimental evidence that 
similar effects may be seen in man (in addition to the clinical observations described above).  In primary 
human macrophages, ACh inhibits the LPS-stimulated release of TNF-Œ±, IL-1Œ≤, IL-6, and IL-18, but has 
no effect on IL-10.33,41  In human monocytes, stimulation of Œ±7nAChR suppresses LPS-associated 
expression of CD14, TLR4, CD40, ICAM-1, and B7.1.42 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
4 
Revised 9/2/14 
In our study (described in the sub-section immediately above), we found that the severity of HIV-AN was 
correlated with the Veteran‚Äôs Aging Cohort Study (VACS) index, which itself has been shown to be 
correlated with inflammation.5  This suggests that HIV-AN could also be associated with inflammation.  
To our knowledge, a potential role for cholinergic anti-inflammatory effects in HIV has been tested 
directly by [CONTACT_554681]-of‚Äì concept study examining 19 HIV-infected patients, who were not 
CART-treated.43  Participants were randomized to receive a low dose of the acetylcholinesterase inhibitor 
(AChEI) pyridostigmine (30mg PO tid) or placebo.  Participants who received pyridostigmine exhibited a 
reduction of CD4+ T cell activation (defined as the percent of cells expressing CD69), as well as in vitro 
reduction of T cell proliferation, decrease of IFN-Œ≥ production, and increase of IL-[ADDRESS_728531] demonstrated that HIV-AN is common in CART-treated individuals and 
commonly involves vagal dysfunction.  However other than a single study of 19 participants,43 there has 
been no attempt to study the intersection of these important and interrelated conditions, in order to 
determine whether vagal dysfunction contributes to the pro-inflammatory state seen with chronic HIV.   
 
3) Setting of the Human Research 
All research procedures will be conducted at Mount Sinai.  All potential participants will be 
identified and recruited at Mount Sinai.  There will be no active recruitment outside of Mount 
Sinai, however if patients or providers at other sites become aware of the study we may accept 
referrals.  All study procedures will be conducted on the main campus of Mount Sinai, [ADDRESS_728532], Annenberg building, Second Floor; or at [ADDRESS_728533] 5th Floor (depending on 
appointment availability).   
4) Resources Available to Conduct the Human Research 
As described below, the study has two phases.  Participants in phase [ADDRESS_728534] 35-4 5 participants eligible for phase 2.  This is based on the estimate that 45% of phase 1 
participants will be eligible for phase 2.   
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
5 
Revised 9/2/14 
As described in greater detail in the ‚ÄúRecruitment Methods‚Äù section,  we plan to recruit patients 
already known to us from previous and ongoing research studies and/or clinical care, and patients 
not previously known to us from the Jack Martin Fund Clinic (JMFC).  Eligibility rests in part on 
the results of autonomic testing.  We are currently aware of about 30 eligible patients meeting 
eligibility criteria including the appropriate autonomic testing results.  Based on our prior studies 
in this population, we estimate that about 15% of JMFC patients will meet study criteria, and that 
this will be somewhat higher (~20%) in our research population since these patients are pre-
selected for criteria (such as older age) that makes AN more likely.   There are currently about 
[ADDRESS_728535] access to an eligible population 
of about 265, from which we will need to recruit 50-70.    
Eight persons will be involved with the study: Jessica Robinson-Papp MD MS who is the PI [INVESTIGATOR_554657] a whole and interpret and oversee the autonomic testing; Susan Morgello, 
MD who will oversee all the non-routine laboratory testing (e.g. cytokines); Gina Sam, MD who 
will oversee the hydrogen breath testing; Josef Machac MD who will oversee the gastric emptying 
scintigraphy ; Emma Benn PhD who will assist [CONTACT_60966]-Papp with the statistical analyses; 
research manager Mary-Catherine George; research coordinator Alexandra Nmashie MD; and 
Sandeep Sharma, Dr.PH.  The last three staff members will oversee the coordination of the 
project.   
[CONTACT_554706] is the PI [INVESTIGATOR_554658] (MHBB), and is [CONTACT_60966]-Papp‚Äôs 
research mentor.  She has extensive experience in neuroAIDS research over decades and will use 
the infrastructure of the MHBB to help [CONTACT_60966]-Papp with the laboratory aspects of this 
project.  [CONTACT_307099] is a gastroenterologist with additional sub-specialty training in 
neurogastroenterology and GI motility.  She has extensive clinical experience diagnosing and 
treating GI dysmotility.  [CONTACT_554707] is board certified in internal medicine, nuclear medicine, and 
cardiology, and has been an integral part of the nuclear medicine department at Mount Sinai for 
over [ADDRESS_728536]. Robinson-Papp‚Äôs prior studies.  [CONTACT_554708] has 
worked with [CONTACT_60966]-Papp as a research coordinator on multiple prior studies, including a 
recent study which examined autonomic function in HIV.   
In order to ensure that all persons involved with the study are adequately trained, [CONTACT_60966]-
Papp will review the protocol in detail with all study staff prior to beginning any study procedures, 
and as needed throughout the study.  Questions and an open dialog among the study staff will be 
encouraged.   
5) Study Design 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
6 
Revised 9/2/14 
a) Recruitment Methods 
Participants will be drawn from three main sources: th e Jack Martin Fund Clinic (JMFC), 
where [CONTACT_60966]-Papp is the attending neurologist,  other research studies in which [CONTACT_240929]-Papp is an investigator, and the FPA Neurodiagnostic Center, which is the other 
location (in addition to JMFC) where [CONTACT_60966]-Papp‚Äôs sees patients.  We will also 
consider patients referred by [CONTACT_554682], but do not have an active 
recruitment plan for these sources.   
JMFC patients will be initially pre-screened using a Mount Sinai Data Warehouse (MSDW) 
Se
arch.  We will create a de-identified dataset from the MSDW that includes all JMFC patients 
with at least1 visit in calendar year 2015, who are being treated with CART (N‚âà700).  The 
dataset will include the following information relevant to pre-screening for this study: HIV-[ADDRESS_728537] the 
patients‚Äô names and medical record numbers, and the name [CONTACT_554701], 
who is very likely to be the primary care provider.  A waiver of informed consent will be 
requested for this portion of the study.  This information will be requested without linkage of 
this new identifying information to the pre-existing de-identified dataset, so as to minimize the 
amount of PHI obtained.  It is likely that some of these patients will be patients of [CONTACT_240929]-Papp, and those patients will be contact[CONTACT_43417].  For patients who are not patients 
of [CONTACT_60966]-Papp, we will initially contact [CONTACT_13917], and ask whether in their opi[INVESTIGATOR_554659], and might be interested in participating.  If the 
provider thinks the patient would qualify, might be interested, and would not find contact 
[CONTACT_554683], the patient will be contact[CONTACT_554684] (typi[INVESTIGATOR_554660]).  Initial contact [CONTACT_554685].  More detailed information will 
be provided only if the patient assents.  With the patient‚Äôs permission, this will include mailing 
a copy of the informed consent to the patient in advance of the screening visit so that they have 
time to review it, discuss it with others and prepare questions for the study team.  The research 
team will not review the subject‚Äôs charts for HIV information prior to obtaining informed 
consent. 
Patients who are known to [CONTACT_60966]-Papp (either clinically or through research) who she 
believes to be eligible and open to participation in research will be contact[CONTACT_43417].  Patients 
who are referred to the study will also be contact[CONTACT_43417]. 
There is also a previously IRB approved printed recruitment flyer which is included with this    
submission. 
b) Inclusion and Exclusion Criteria 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
7 
Revised 9/2/14 
Inclusion criteria are: 
ÔÇ∑ ‚â•18 years old 
ÔÇ∑ Documented evidence of HIV-1 infection 
ÔÇ∑ Stable CART therapy for ‚â•3 months  
ÔÇ∑ Most recent HIV-1 viral load ‚â§100 copi[INVESTIGATOR_014]/ml (value must be within the past six 
months) 
ÔÇ∑ English speaking 
ÔÇ∑ Able to tolerate autonomic testing (e.g. able to stand, able to perform Valsalva 
maneuver).   
ÔÇ∑ If using nicotine-containing products willing to refrain from use for 24 hours prior to all 
testing
 procedures (autono mic reflex screen, breath testing,  and gastric emptying) 
ÔÇ∑ ‚â•1 GI symptom on the Survey of Autonomic Symptoms  (SAS)47 
Exclusion criteria are: 
ÔÇ∑ Diagnosis known to cause autonomic dysfunction other than HIV (e.g. Parkinson‚Äôs 
disease, diabetes) 
ÔÇ∑ Diagnosis known to cause GI dysfunction other than HIV (e.g. peptic ulcer disease, 
infectious diarrhea) 
ÔÇ∑ Current use of any of the following classes of medications (due to potential for significant 
autonomic or GI effects, interaction with pyridostigmine, o r interference with one or more 
of the testing procedures) 
o Prokinetics (e.g. metoclopramide) 
o Anti-diarrheals (e.g. loperamide) 
o Antibiotics 
o Mefloquine 
ÔÇ∑ Medical or psychiatric conditions precluding safe participation in study procedures or 
deemed likely to result in hospi[INVESTIGATOR_227074].  
ÔÇ∑ The presence of one or more of the following diagnoses which render the Valsalva 
maneuver relatively or absolutely contraindicated: uncontrolled glaucoma, aortic stenosis, 
myocardial infarction in the last 6 months, other retinopathy or unclipped cerebral 
aneurysm.  
ÔÇ∑ The presence of one or more of the following diagnoses which impede interpretation of 
autonomic testing: cardiac arrhythmias or pacemakers.   
ÔÇ∑ An allergy to eggs (contraindication to gastric emptying scintigraphy)  
ÔÇ∑ Any of the following laboratory results: 
o Positive pregnancy test (administered to women of childbearing potential only) 
o Urine toxicology screen positive for stimulants (e.g. amphetamines, cocaine) or 
opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438].   
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
8 
Revised 9/2/14 
Screening procedure: 
No research procedures will be performed prior to obtaining informed consent.  The 
majority of inclusion/exclusion criteria are ascertainable from the patient and the medical 
record, with the following exceptions (in order of increasing complexity): the SAS which 
is a questionnaire; pregnancy and toxicology screening which requires a urine sample; and 
the CASS which requires autonomic testing.  In order to limit participant exposure to 
unnecessary testing, the screening will be performed in a tiered manner.  The simplest 
criteria (i.e. those items obtainable from the medical record) will be assessed first, and the 
most involved (i.e. the autonomic testing) will not be performed unless all other criteria 
have been satisfied.  The screening process will end at the first evidence of ineligibility.  
c) Number of Subjects 
We intend to pre-screen about [ADDRESS_728538]. Robinson-Papp or referred to the study.  We 
will enroll (i.e. obtain informed consent from) up to 250 participants as required to identify 
up to 100 participants eligible for full baseline assessment, and up to 4 5 participants to 
enter the intervention phase. 
d) Study Timelines 
The maximum expected duration of individual subject participation is 6  months for 
participants who complete both phase 1 and 2.  For patients who complete phase 1 but are 
found to be ineligible for phase 2, study participation will be much shorter, typi[INVESTIGATOR_897] 1-2 
weeks.  The duration anticipated to enroll all study subjects is 18 months.  The estimated 
date for the investigators to complete this study (complete primary analyses) is 24 months. 
e) Endpoints 
The study endpoints are: vagal sub-score of mCASS (vagal dysfunction, calculated from 
autonomic testing), GE T¬Ω (GI dysmotility, calculated from gastric emptying 
scintigraphy), CRP and IL-6 (immune activation), LPS (bacterial translocation), total 
hydrogen excretion in the breath (ppm x min) over 2 hours following ingestion of 50g 
glucose (SIBO).  Secondary measures include: vagal baroreflex sensitivity; Valsalva ratio; 
heart rate variability with deep breathing; percent gastric emptying at 1-4h; CRP; sCD14. 
Participants who are eligible for the intervention phase of the study in which they will 
receive treatment with pyridostigmine will be monitored for adverse events.  Adverse 
events, including anticipated medication side effects, may be grounds for discontinuation 
of study drug, based on the judgment of the PI [INVESTIGATOR_554661].  If the 
study drug is to be discontinued early, and it is a non-emergent discontinuation, effort will 
be made to perform follow-up measurements (see intervention visit 3 in the subsequent 
section) prior to discontinuation of the drug. 
f) Procedures Involved in the Human Research 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
9 
Revised 9/2/[ADDRESS_728539] phase (baseline) cross-sectional data will be 
collected for correlational analyses, and for determination of participant eligibility for 
phase two.  In the second phase, the subset of eligible participants will be treated with 
pyridostigmine for [ADDRESS_728540].  A summary of study visits is provided here, followed by a detailed description 
of each of the individual procedures.  All procedures are performed solely for the research, 
and not for clinical purposes. However all tests to be performed are standardized tests 
which are performed clinically.  
Screening visit: All participants will be seen for a screening visit which consists of 
informed consent and assessment of eligibility including: documentation of medical 
history and current medications; the SAS questionnaire; brief neurologic examination; 
urine pregnancy and toxicology screening; and autonomic function testing.  All 
procedures, including the informed consent process will take place on Annenberg [ADDRESS_728541] prior to any research 
related activities.  Participants meeting all inclusion/exclusion criteria will then proceed to 
the baseline visit.  The screening visit will last about approximately [ADDRESS_728542] or questionnaire that reveals in eligibility, in w hich case the screening process will be 
stopped and so will be shorter in duration.  
Baseline visit:  The baseline visit may occur over several days (7-10 days) and will include  
hydrogen  breath test  (approximately 3.5 hours), blood collection  (approximately 2 -3 
tablespoons) , gastric emptying scintigraphy  (approximately 4 hours) , and questionnaires  as 
listed below (approximately 30 minutes) .   
Participants will then move on to additional visits if they meet ALL of the following 
criteria: 
1) CASS ‚â• [ADDRESS_728543] one abnormal vagal parameter on the autonomic function testing 
(vagal baroreflex sensitivity; Valsalva ratio; heart rate variability with deep breathing). 
2) Abnormality in gastric emptying scintigraphy (retention at 30 min: <70%; 60 
min:<30%, >90%; 120 min: >60%; 180 min: >30%; 240 min: >10%). 
3) No use of pyridostigmine within the past 6 months   
4) No contraindication to pyridostigmine including current: mechanical intestinal or urinary 
obstruction, known hypersensitivity to anticholinesterase agents, bradycardia, cardiac 
arrhythmias, or asthma or chronic obstructive pulmonary disease.  
Participants with an abnormality in hydrogen breath testing suggestive of small intestinal 
bacterial overgrowth (SIBO), will be informed of this finding (which m ay warrant 
treatment).  Permission will also be sought from the participant to convey this information 
to their primary care provider (PCP).  The participant will not have any further study visits 
until a course of treatment has been decided upon.   
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
10 
Revised 9/2/[ADDRESS_728544] is normal the participant will proceed to intervention visit 1 only if all the above 
criteria are met (1-4). 
If the PCP decides that oral antibiotics are not indicated, and the above criteria 1, 3 and 4 
are met then the participant will proceed to intervention visit 1.       
For participants not meeting the criteria, study participation will end with the baseline visit. 
Intervention visit 1: Participants will begin treatment with pyridostigmine 30mg PO tid.  
This visit will last about [ADDRESS_728545]: Participants will be contact[CONTACT_554686]. 
Intervention visit 2:  Approximately [ADDRESS_728546] less than one hour.  
Intervention visit 3: Approximately [ADDRESS_728547] (for women of childbearing potential) will also be repeated at this visit prior 
to other testing.  This visit will be conducted in essentially the same manner as the baseline 
visit.  Pyridostigmine will be discontinued at the end of this visit . 
Intervention visit 4 : Approximately 10 weeks after initiation of study drug (which is 
approximately 2 weeks after cessation of study drug), participants will repeat all 
questionnaires and be assessed for adverse events.   This visit is expected to last less than 
one hour.  
Autonomic function testing is performed under the supervision of [CONTACT_60966]-Papp.  
This is a standard battery of non-invasive physiologic tests to assess autonomic nervous 
system function.10,49  The patient is asked to lie supi[INVESTIGATOR_554662].  
Quantitative Sudomotor Axon Reflex Testing (QSART) is performed by [CONTACT_1299] a capsule 
containing acetyl choline (ACh) on the skin in four standardized locations (forearm, 
proximal leg, distal leg and foot).  The capsule is attached to a computer system which 
delivers a small continuous electrical stimulus to the capsule causing iontophoresis of ACh 
into the skin.  The ACh causes a reflexive sweat response which is collected by [CONTACT_554687].  The total sweat volume is measured by [CONTACT_554688].  Following the QSART, a non-invasive continuous beat- to-beat blood 
pressure monitoring device is attached to the participant‚Äôs finger (Nexfin system; 
www.bmeye.com) and a 3-lead surface electrocardiogram is attached to the chest.  
Continuous blood pressure (BP) and heart rate (HR) are recorded during Valsalva 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
11 
Revised 9/2/14 
maneuver (VM; forced exhalation to a pressure of 40 mmHg for 15 seconds) and during a 
standardized paced deep breathing exercise (heart rate response to deep breathing; HRDB).  
BP and HR responses during VM are analyzed manually according to the Composite 
Autonomic Scoring Scale (CASS).  For the HRDB test, the average change in HR from 
peak inspi[INVESTIGATOR_554663] 5 consecutive cycles of breath and compared 
to standardized values.  Finally the participant is secured to the tilt table and tilted to the 
upright position.  Continuous HR and BP are recorded for 10 minutes (as tolerated).  
Criteria for immediate return to the supi[INVESTIGATOR_554664]: 1) the patient becomes 
symptomatic or asks to end the test; 2) there is hemodynamic evidence of orthostatic 
intolerance (HR increase of >30 bpm, systolic BP decrease >20 mmHg, diastolic BP 
decrease >10 mmHg); 3) the clinician‚Äôs discretion. 
The hydrogen breath test is currently in clinical use for the detection of small intestinal 
bacterial overgrowth (SIBO) and is performed under the supervision of [CONTACT_307099].51  Breath 
samples are obtained throughout the testing by [CONTACT_554689] a plastic 
bag.  The hydrogen content of the samples is measured using a commercially available 
analyzer (Quintron; http://www.breathtests.com ).  A baseline breath sample is collected.  
The participant then ingests 50g of glucose after which breath samples are collected every 
[ADDRESS_728548] meal, consisting of four ounces (118 mL) of liquid egg whites 
(equivalent of 2 eggs) (e.g., Eggbeaters [ConAgra Foods, Inc.] or equivalent generic liquid 
egg whites), mixed with 0.[ADDRESS_728549] anterior  and posterior 
128x128 matrix images are aquired for 60 seconds at four time points (0, 1, 2, 3 and 4 
hours) on the same gamma camera.  The subject must remain in the upright sitting or 
standing position the entire [ADDRESS_728550] exposure is the large 
intestine, which receives 2.1 mSv. 
Routine blood tests (CRP, T cell enumeration (CD4/CD8), HIV-1 viral load) will be 
performed by [CONTACT_317702]‚Äôs clinical laboratory services.  Blood for experimental assays 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
12 
Revised 9/2/14 
(IL-6, LPS, sCD14 ) will be processed in the laboratory of [CONTACT_554709], utilizing the 
infrastructure of the MHBB.  Additional markers may also be added based on the 
availability of funding (e.g. IFN-Œ≥, IL1-Œ≤, IL-10, IL-18, TNF-Œ±, sCD163, IL-18, HMGB-1, 
HO-1 and TLR4 mRNA quantitation). 
The questionnaires will include: Survey of Autonomic Symptoms,47 the Composite 
Autonomic Symptom Score (COMPASS ),56 Medical Outcomes Study (MOS-HIV) quality 
of life questionnaire.[ADDRESS_728551] the study team with any safety concerns at any time, and ensure 
that they know how to do so. 
g) Specimen Banking 
Blood samples identified by [CONTACT_74218], will be stored within the laboratories of the 
MHBB.  Other data will include the specimen type and the date of collection.  This is not 
optional because specimens must be analyzed in batches in order to minimize cost.  In 
addition, PBMCs from the blood samples will be frozen viably after Ficoll-Hypaque 
separation (as per MHBB protocol), so that HO-[ADDRESS_728552] access to these 
specimens (as necessary to do their jobs) which will be clearly marked as separate from 
MHBB specimens.  Specimens will not be released to investigators outside this study. 
h) Data Management and Confidentiality 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
13 
Revised 9/2/[ADDRESS_728553]. Robinson-Papp‚Äôs locked office.  Only study staff will have access to these paper 
records, and only as required to perform their roles.  The participant demographics form 
and the informed consent document, which contain identifying data will be separated from 
the other documents.  All other documents will be identified by [CONTACT_2299]‚Äôs study 
identification (ID) number only.  De-identified data will be entered into a password 
protected database that is housed on a secure, encrypted, Mount Sinai network drive.  No 
data will be sent out or received.   All GI testing data will be reviewed for quality by [CONTACT_6283]. 
Machac or Sam as appropriate.  All laboratory data will be reviewed for quality by [INVESTIGATOR_124]. 
Morgello or her delegate.  All autonomic testing data and all data overall will be reviewed 
by [INVESTIGATOR_124]. Robinson-Papp to assure its quality, and also by [INVESTIGATOR_124]. Benn who will look 
particularly for statistical evidence of errors e.g. outliers.  In addition the database will be 
programmed to only accept data within an expected range, which minimizes error.   
Eighty participants in phase 1 provide >80% power (Œ±=0.05) for detecting a ‚ÄúMedium‚Äù 
effect size for both ‚Äúpaths‚Äù depi[INVESTIGATOR_514979] 1, where ‚ÄúMedium‚Äù corresponds to an effect 
accounting for 13% of the variance (as per Cohen‚Äôs criteria).  However since all phase [ADDRESS_728554] 80% power to detect a standardized difference of 
0.[ADDRESS_728555] 45% of participants with 
HIV-AN to have vagal dysfunction, and based on a prior study of HIV-infected 
participants with GI symptoms, we expect a similar percentage with abnormal gastric 
emptying.  Although the extent of overlap between these two groups is not known, in 
diabetics 80% of those with vagal dysfunction have gastric emptying abnormalities.  Thus 
we estimate that about 35-40% of phase 1 participants will meet criteria for phase 2, and 
therefore 80-85 phase 1 participants should be sufficient.  However we recognize that these 
estimates contain significant uncertainty, thus planning for up to 100 phase 1 participants 
provides a safety margin. 
Primary measures for the analyses will be: vagal sub-score of mCASS (vagal dysfunction), 
GE T¬Ω (GI dysmotility), IL-6 (immune activation), LPS (bacterial translocation), total 
hydrogen excretion in the breath (ppm x min) over 2 hours following ingestion of 50g 
glucose (SIBO).  Secondary measures include: vagal baroreflex sensitivity; Valsalva ratio; 
heart rate variability with deep breathing; percent gastric emptying at 1-4h; CRP; sCD14.  
The remainder of the cytokines and inflammatory mediators described above will be used 
in exploratory analyses to generate hypotheses regarding the function of the cholinergic 
anti-inflammatory pathway and the effects of pyridostigmine in HIV.  Covariates to be 
included in all analyses as appropriate are: age, gender, duration of known HIV infection, 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
14 
Revised 9/2/14 
current and nadir CD4+ cell count.  All analyses will be two-tailed, conducted at the Œ± = 
0.05 level, and adjusted for multiple comparisons as appropriate. 
Specific Aim 1 is to determine whether vagal dysfunction is associated with immune 
activation in CART-treated participants with HIV-AN, and if so to estimate the extent to 
which this association is mediated by [CONTACT_554679] (i.e. slowed motility, SIBO, microbial 
translocation) versus direct effects of vagal dysfunction.  Initially, Spearman rank 
correlations will be performed pairwise between IL-6, the vagal sub-score of mCASS, GE 
T¬Ω, breath hydrogen excretion, and LPS. If correlations are demonstrated we will use the 
method of direct acyclic graphs (DAG) to test the paths hypothesized in figure 1.  This 
method can also be used to test whether any of the secondary measures of the constructs in 
the DAG support the hypothesized paths. The rules for testing the various paths in a DAG 
for significance are based on regression coefficients obtained from statistical models 
constructed using the particular DAG under investigation.  Statistical testing of the 
regression coefficients will be carried out using PRODCLIN software.  Power for the 
effects of mediation variables in the DAGs is estimated using tables provided by [CONTACT_554690].  Since different DAGs have different numbers of variables in them, with 
many
 distinct possible paths, power is calculated for any given ‚Äútriangle‚Äù formed by a 
mediator (M) between a predictor (X) and an outcome (Y).  The power is given in terms of 
Small, Medium, and Large effect sizes for the paths.   
Specific Aim 2 is to investigate whether pyridostigmine reduces immune activation and/or 
improves GI function, and if so to estimate the extent to which the reduction in immune 
activation is mediated by [CONTACT_554679] (i.e. improved motility, SIBO, microbial translocation) 
versus direct cholinergic effects.  Following appropriate transformation of non-normally 
distributed variables, linear mixed models for longitudinal data will be used to evaluate the 
longitudinal trend in each of the following outcomes in participants who receive 
pyridostigmine: IL-6, GE T¬Ω, breath hydrogen excretion and LPS.  In these models, the 
dependent variable will be the outcomes listed above, and the independent variables will be 
time (fixed effect) and subject (random effect).  We will also construct a multivariate 
mixed linear model to estimate the contribution of each variable‚Äôs change to the change in 
IL-6.  In secondary analyses we will perform similar calculations using secondary 
measures of immune activation, GI motility, and translocation.   
i) Provisions to Monitor the Data to Ensure the Safety of Subjects 
 
Part I: Elements of a Data and Safety Monitoring Plan 
1. [CONTACT_60966]-Papp is the principal investigator [INVESTIGATOR_554665]. 
 
MSSM Principal Monitor: 
Principal Investigator  
[INVESTIGATOR_9963]:  Robinson-Papp  
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
15 
Revised 9/2/[ADDRESS_728556] Name: [CONTACT_554702]: Assistant [CONTACT_78052]:  Neurology 
Mailin
g Address:  Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1052, 
[LOCATION_001], NY [ZIP_CODE] 
Phone: [PHONE_11536]  
Fax: 212-
987-3301 
E-m
ail: [EMAIL_10549]  
 
MSSM Additional Monitor: 
Independent 
Last Name: [CONTACT_554703]-Caprio  
First Name: [CONTACT_554704]: Assistant [CONTACT_554710]
tment: Medicine, Infectious Diseases 
Mailing Address: Mount Sinai Medical Center,   , [LOCATION_001], 
NY [ZIP_CODE] 
Phon
e: [PHONE_11537]  
Fax: 212-
824-2312  
E-m
ail: [EMAIL_10550]  
 
2. [CONTACT_60966]-Papp is a neurologist with special expertise in caring for patients with HIV/AIDS 
and patients with neuromuscular disorders.  She has experience with the study population and 
with the study drug and will be involved with the day to day activities of the study and is 
therefore the most suitable person to be the primary safety monitor, particularly since this is an 
open label study and so there is no difficulty regarding blinding.  [CONTACT_26429]-Caprio is an 
internist and an infectious disease specialist, focusing in HIV/AIDS treatment.  She is the 
medical director of the clinic from which a large proportion of the research participants will be 
drawn.  [CONTACT_26429]-Caprio and [CONTACT_60966]-Papp work together at the clinic and have 
several mutual patients.  The rationale for selecting [CONTACT_26429]-Caprio was that as the 
director of the clinic, and as a clinician not involved in the research, her primary interest is in 
the safety and wellbeing of the patient population. We also wanted an independent monitor 
with a gener
al medical background so as to complement [CONTACT_60966]-Papp‚Äôs more focused 
neurologic expertise. 
 
3. Adverse events (AE) will be monitored for safety, including those events related and unrelated 
to the study procedures.  All such events will be characterized as described in item 7, and 
documented in t
he AE log.  In addition to AEs, self-reported adherence to study drug will be 
queried including the reason for any missed doses.  Any drop-outs from the interventional 
phase will
 also be recorded, along with the reason. 
 

 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
16 
Revised 9/2/[ADDRESS_728557] 
semi-annually. 
 
5.   Should an unanticipated event occur related to drug, the study will be halted while the need for 
modi
fication is considered.  A report will be provided both to the IRB and funding agency.  If 
modifications are deemed necessary, these will also be presented to the IRB and funding 
agency for review and approval.   
 
6. There are no dose selection procedures.  The same dose (30mg PO tid) will be used for all 
participants throughout the entire 8-week interventional period of the study. This is a 
commonly used starting dose for pyridostigmine in clinical practice, and lower doses are not 
practicable due to the lack of smaller pi[INVESTIGATOR_316962].  This low dose has been chosen to minimize 
toxicity.  
 
7. AEs will be classified as mild, moderate or severe based upon the following criteria:   
ÔÇ∑ Mild: symptoms do not alter the subject‚Äôs normal functioning. 
ÔÇ∑ Moderate: symptoms produced some degree of impairment to function but are not 
dangerous, uncomfortable or embarrassing to the subject.  
ÔÇ∑ Severe: symptoms are dangerous to the subject‚Äôs well-being and cause significant 
impairment of function or incapacitation. 
 
The relationship of the AE to the treatment will be classified as follows:  
ÔÇ∑ Related:  there is good reason and sufficient evidence to assume that there is a causal 
relationship with the treatment.   
ÔÇ∑ Not related:  there is good reason and sufficient evidence to exclude a causal 
relationship with the treatment.  
 
All AEs will require the investigator to obtain adequate information to determine the outcome of 
the AE and to assess whether it meets criteria as a serious adverse event (SAE), which requires 
immediate notification to the funding agency and IRB.   The investigator will obtain sufficient 
information to determine the causality of the AE (i.e. treatment or other cause); and provide an 
opi[INVESTIGATOR_554666] (i.e., whether they consider the AE related or not related to the 
study intervention).   Subjects will receive follow up until the AE either resolves completely or 
stabilizes to a level acceptable to the PI.  
 
All SAEs will be reported within 24 hours of the investigator‚Äôs knowledge of the event to the IRB 
and/or funding agency.  An SAE is any AE that fulfills one of the following criteria:   
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
17 
Revised 9/2/14 
ÔÇ∑ Results in death  
ÔÇ∑ Is life threatening and places the subject at immediate risk of death 
ÔÇ∑ Results in hospi[INVESTIGATOR_059] 
ÔÇ∑ Results in significant disability/incapacity, where the disability is a substantial 
disruption of a person‚Äôs ability to conduct normal daily life functions 
ÔÇ∑ Is an important medical event that may not result in death, be life threatening, or 
require hospi[INVESTIGATOR_059], but which based upon the appropriate medical judgment may 
require medical and/or surgical intervention to prevent one of the outcomes listed 
above   
 
8. All GI testing data will be reviewed for quality by [CONTACT_6283]. Machac or Sam as appropriate.  All 
laboratory data will be reviewed for quality by [INVESTIGATOR_124]. Morgello or her delegate.  All autonomic 
testing data and all data overall will be reviewed by [INVESTIGATOR_124]. Robinson-Papp to assure its quality 
(i.e. accuracy and completeness), and also by [INVESTIGATOR_124]. Benn who will look particularly for statistical 
evidence of errors e.g. outliers.  In addition the database will be programmed to only accept 
data within an expected range, which minimizes error. 
 
9. Should a temporary or permanent suspension of the study occur, this will be reported to the 
PPHS/IRB and the funding agency. 
  
 A data safety monitoring board will not be formed. 
 
j) Withdrawal of Subjects 
A subject may be withdrawn from the research without their consent if they exhibit 
behavior that is disruptive to study procedures.  Prior to such a termination, the patient will 
be assessed by [INVESTIGATOR_124]. Robinson-Papp, and then informed of the termination in a calm, secure 
and private setting, and the encounter documented in writing.  If termination occurs further 
data collection will not continue.  However we anticipate that our familiarity with this 
patient population, close collegial relationship with JMFC primary care providers and the 
screening process will help us avoid this scenario.  Participants may also be withdrawn 
without their consent if continuation in the study is deemed inappropriate due to a change 
in medical condition, for example if a subject becomes acutely ill and is hospi[INVESTIGATOR_057]. 
Participants may voluntarily withdraw from the protocol at any time.  A member of the 
study staff will meet privately with any participant wishing to withdraw in order to 
determine the reason if possible, and also to determine if the participant would be willing 
to consider partial withdrawal, which might include termination of the intervention, but 
completion of the remaining study assessments.     
6) Risks to Subjects 
The procedures involved in the research include: documentation of medical history, 
physical/neurologic exam, answering of questionnaires, autonomic testing, gastric 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
18 
Revised 9/2/14 
emptying scintigraphy, hydrogen breath testing, collection of blood and urine, answering 
of questionnaires, and for a subset of participants taking pyridostigmine 30mg PO tid for 8 
weeks. 
We do not foresee significant psychological, social, financial, legal or economic risks.  The 
main risks of documentation of medical history, physical/neurological exam, and 
answering of questionnaires relate to issues of privacy and confidentiality.  This is 
discussed in sections 5h and 9. 
The potential physical risks to subjects include those associated with venipuncture, gastric 
emptying scintigraphy, hydrogen breath testing, autonomic testing and in a subset of 
participants: pyridostigmine.  Risks associated with venipuncture include pain and 
bruising.  The discomfort associated with the insertion of the needle is likely to be 
experienced by [CONTACT_554691], more significant pain is unlikely.  Mild bruising 
may occur in a minority of participants, more significant bruising is unlikely.  The main 
risk of ga
stric emptying scintigraphy is that of radiation exposure.  All participants will be 
exposed, but the small amount of radiation involved is not considered to be clinicall y 
significant.  There is essentially no significant risk associated with hydrogen breath testing.  
There are some physical risks associated with autonomic testing.  Valsalva maneuver 
causes brief (< 1 minute) alterations in blood pressure which are unlikely to be of clinical 
significance.  Tilt-table testing may cause hypotension in subjects with autonomic 
dysfunction leading to unpleasant pre-syncopal symptoms or rarely, syncope.  Pre-
syncopal symptoms may occur in a minority of participants, syncope is considered unlikely 
because subjects are immediately returned to the supi[INVESTIGATOR_554667]-syncopal symptoms.  Other potential risks of autonomic testing 
include mild discomfort associated with lying supi[INVESTIGATOR_2525] a prolonged period of time and 
local skin discomfort or irritation from the quantitative sudomotor axon reflex testing.  
These events are considered moderately likely, but not very burdensome.  Loss of 
confidentiality is also a potential risk with these procedures but is considered unlikely, and 
of low burden. 
Pyridostigmine has been in clinical use for over 50 years, primarily in the treatment of 
myasthenia gravis (MG).  The dose used in this study is a common starting dose, the 
maintenance dose used clinically is usually substantially higher and is taken for life.  MG 
is a neurologic autoimmune disease that typi[INVESTIGATOR_554668]-term treatment with 
immunosuppressive medications and can affect children and adults of all ages.  MG 
patients often experience medical co-morbidities including other autoimmune conditions 
and the effects of long term iatrogenic immunosuppression.  The population in this study is 
similar to the MG population in that they are medically complicated adults with varying 
degrees of immunosuppression.  However well-controlled HIV is an inclusion criterion for 
this study, and so we will not have participants with advanced immunosupression.  
According to the FDA, there are no known long-term side effects of pyridostigmine 
(http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/uc
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
19 
Revised 9/2/14 
m130343.htm#8 ).  Possible short term side effects included in the prescribing information 
are: stomach cramps, gas, diarrhea, nausea, increased urge to urinate, drooling, sweating, 
headaches, dizziness, eye tearing, blurred vision, runny nose, shortness of breath, acid 
stomach, including heartburn or reflux, tingling, muscle twitching, weakness, or crampi[INVESTIGATOR_007].  
The incidence of these side effects is not reported in the prescribing information as it 
would be for a more recently developed drug, however clinical experience suggests that 
side effects are fairly infrequent at the low dose used in this study.  When side effects do 
occur, they are short -lived, resolving within a few hours or less.  We expect the dose used 
in this study to be well-tolerated.  An excerpt from the drug brochure regarding adverse 
effects is included below for completeness: 
‚ÄúThe side effects of pyridostigmine bromide are typi[INVESTIGATOR_554669], muscarinic and 
nicotinic. Muscarinic side effects include abdominal cramps, bloating, flatulence, diarrhea, 
emesis, increased peristalsis, nausea, hypersalivation, urinary incontinence, increased 
bronchial secretion, diaphoresis, miosis, and lacrimation. Nicotinic side effects are 
comprised c
hiefly of muscle cramps, fasciculations, and weakness.  Pyridostigmine is a 
quaternary ammonium compound and does not readily cross the blood-brain barrier. 
Compared to the peripheral effects of pyridostigmine bromide, central nervous system 
manifestations are less frequent and less serious, primarily consisting of headache and 
vertigo, with minor and clinically insignificant changes in heart rate, blood pressure, and 
respi[INVESTIGATOR_4806]. Extremely high doses may produce CNS symptoms of agitation, 
restlessness, confusion, visual hallucinations, and paranoid delusions. Electrolyte 
abnormalities, possibly resulting from high serum bromide concentrations, also have been 
reported. Death may result from cardiac arrest or respi[INVESTIGATOR_554670].   
 
‚ÄúIn a controlled study of 90 healthy volunteers comparing pyridostigmine 30 mg every 8 
hours to placebo for 21 days, the following incidence of adverse events was reported. 
 
Table 1 Incidence of Adverse Events  
Event:  % 
Pyridostigmine  
N = 60 % 
Placebo 
N = 30 
Diarrhea  7  0 
Abdominal Pain  7  0 
Dysmenorrhea  5  0 
Twitch  3  0 
Myalgia  2  0 
Dry Skin  2  0 
Urinary 
Frequency  2  0 
Epi[INVESTIGATOR_3940]  2  0 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
20 
Revised 9/2/14 
Amblyopia  2  0 
Hypesthesia  2  0 
Neck pain  2 0 
 
Other less common adverse events seen during controlled and uncontrolled clinical trials 
for pyridostigmine include the following: 
¬∑ Pulmonary: Exacerbation of acute bronchitis and asthma 
¬∑ Cardiovascular: Elevated blood pressure, decreased heart rate (4-6 beats per minute), 
chest tightness 
¬∑ Eyes: Change in vision, eye pain 
¬∑ Neurologic: Headache, hypertonia, difficulty in concentrating, confusion, disturbed 
sleep, tingling of extremities, numbness of the tongue 
¬∑ Skin: Increased sweating, rash, alopecia 
¬∑ Digestive: Vomiting, borborygmi, nausea, bloating, flatulence 
¬∑ General: Warm sensation, lethargy/drowsiness, depressed mood 
 
During safety studies at the recommended dosage, there were two reports of loss of 
consciousness, one of which also included urinary and fecal incontinence, stiffness of the 
upper torso and arms, post syncopal skin pallor, post syncopal confusion, and post 
syncopal weakness (suggesting a seizure event).As with any compound containing 
bromide, a skin rash may be observed in an occasional patient, which usually subsides 
promptly upon discontinuance  of the medication .‚Äù 
 
7) Provisions for Research Related Harm/Injury 
The study team will be available for the participant should any anticipated or unanticipated 
injury occur.  The team will assess the patient and facilitate referral to the appropriate medical 
care.  All necessary care will be billed in the manner customary for clinical services, i.e. to the 
patients‚Äô insurance and/or the patients themselves as applicable.    
8) Potential Benefits to Subjects 
Individual participants may experience no benefit.  Those treated with pyridostigmine may 
benefit from reduction in inflammation or amelioration of GI symptoms.  Others may 
experience satisfaction from contributing to scientific research in HIV.  Some participants 
may benefit if undiagnosed neurologic or GI conditions are revealed by [CONTACT_554692].   
9) Provisions to Protect the Privacy Interests of Subjects 
 
As described above in the recruitment section, participants will be sought from three main sources : the 
Jack Martin Fund Clinic (JMFC), other research studies in which [CONTACT_60966]-Papp is an 
investigator, and [CONTACT_60966]-Papp‚Äôs clinical practice.  In recruiting subjects, consideration must 
be given to a person‚Äôs desire to control how, and with whom, they interact and communicate.  
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
21 
Revised 9/2/[ADDRESS_728558]. Robinson-Papp will pre-screen potential participants who are known to her to 
determine whether (based on previous interactions) such participants are likely to be eligible and 
to welcome contact [CONTACT_9881].  For potential participants not known to [CONTACT_60966]-
Papp, the first point of contact [CONTACT_554693], who will be asked to make a 
preliminary assessment of eligibility and of willingness to be contact[INVESTIGATOR_530].  In all cases the initial 
contact [CONTACT_554694], prior to initiating a more 
lengthy communication regarding the details.  Care to respect the participants‚Äô privacy will be 
taken in this, and all subsequent communications.  No specific information will ever be left with 
family members or in voice messages.   
 
Throughout the study, ensuring that participants feel comfortable with the study staff and procedures 
will be a high priority.  It is our practice to carefully review all procedures (including timing and 
the necessary space, staff and equipment) for each study visit in advance so that the visits are well 
organized. An organized and punctual visit helps put participants at ease.  All procedures will be 
conducted in a calm and private environment staffed by [CONTACT_554695].  
All procedures will be carefully explain ed before they are performed, and physical exposure will 
be minimized.  Staff always endeavors to be caring and respectful in their communications with 
participants. 
 
It is acceptable and appropriate for members of the research team to approach prospective participants 
because we are very familiar with the population and have expertise in recruiting here in an 
inoffensive manner.  Furthermore, it is our experience that this population usually enjoys 
participating in research, but also feels empowered to decline if the subject is not of interest to 
them. 
10) Economic Impact on Subjects 
In the event of a study-related adverse event or injury, subjects will be responsible for any 
expenses not covered by [CONTACT_150401]. 
 
11) Payments to Subjects 
Participants will be reimbursed $15 0 for completing the screening and baseline visits .  If 
prior to completing the baseline visit they are deemed a screen failure then this payment 
will be prorated as follows: $20 for screen failure prior to autonomic testing, $50 for 
screen failure after autonomic testing.  Participants who enter the interventional phase will 
receive $20 for visits 1, 2 and 4 and $100 for visit 3. All reimbursements are paid in cash at 
each visit. 
12) Consent Process 
Typi[INVESTIGATOR_554671] a potential participant will be by [CONTACT_648].  Once the potential 
participant expresses interest in the study, an informed consent document will be mailed to 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
22 
Revised 9/2/14 
their home for their review (with their permission), and an in person visit will be 
scheduled.  The informed consent document will contain an explanation of all study 
procedures, including risks and benefits, explained in lay language.  The informed consent 
process will be performed at the time of the study visit by [CONTACT_978] [INVESTIGATOR_1660] a delegate.  The 
delegate must have fulfilled all the mandatory regulatory requirements and training, have 
had additional specific training in the protocol, and have undergone a period of 
observation by [CONTACT_978].  At the time of the visit, the informed consent document will be 
reviewed with the participant in a quiet, private setting to ensure understanding of the 
protocol and willingness and ability to adhere to the study procedures.  This is done by 
[CONTACT_554696] a dialogue about the study, asking the participant to 
reiterate protocol procedures, and encouraging the participant to ask questions.  This 
process is then documented in a narrative progress note and in the signed consent 
document.  The team will adhere to ‚ÄúSOP HRP-090 Informed Consent Process.‚Äù   
The
 research will not include children, or cognitively impaired adults who are unable to 
provide informed consent for themselves. 
Non-English Speaking Subjects 
In general subjects will be required to read and understand English, but should a 
participant be eligible whose primary language is Spanish, a Spanish consent form would 
be provided to the PPHS for review in order to include these participants in the study.  
Also, a translator would be arranged for all of the study visits, because the study team does 
not have a member fluent in Spanish. We do not have significant numbers of patients in 
our population who speak neither English nor Spanish. 
Waiver or Alteration of the Consent Process  
We are requesting a waiver of consent (and a HIPAA waiver of authorization) to access data for 
the purposes of pre-screening from the Mount Sinai Data Warehouse (MSDW).  As described 
above in the recruitment section, we currently have a de-identified dataset from the MSDW that 
includes all JMFC patients (N‚âà700 ) with at least 3 visits between 11/1/13-10/31/14, who are 
treated with CART.  The dataset,  which was assembled for an unrelated project, includes several 
variables which are useful for pre-screening for this study.  We are requesting a waiver of 
informed consent in order to obtain from the MSDW a list of potentially eligible patients, which 
will include names, medical record numbers, and the name [CONTACT_554705]-
medications (who is very likely to be the primary care provider) for the patients in our list who 
have an undetectable  HIV-1 viral load, no urine toxicology positive for opi[INVESTIGATOR_858]/opi[INVESTIGATOR_554672], no diagnosis of diabetes, no diagnosis of peptic ulcer disease, and no 
prescriptions for opi[INVESTIGATOR_2573]/opi[INVESTIGATOR_37007].  This information will be requested without linkage of 
the identifying information to the de-identified information so as to minimize the amount of PHI 
obtained.  Also we are using the search to exclude patients who have certain characteristics (e.g. a 
pa
rticular diagnosis, test result, or medication), and so we will have very little specific information 
about the patients who are included on the list.  The process of contact[CONTACT_554697]. 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
23 
Revised 9/2/14 
We believe that this portion of the protocol meets the requirements set forth in criteria set 
#[ADDRESS_728559],  namely:  
ÔÇ∑ This portion of t he research is not FDA-regulated. 
ÔÇ∑ This research does not involve non-viable neonates. 
ÔÇ∑ This portion of the research involves no more than minimal risk to the subjects, namely 
a contact [INVESTIGATOR_507681], after obtaining permission from their healthcare 
provider.  
ÔÇ∑ The waiver will not adversely affect the rights and welfare of the subjects.   
ÔÇ∑ The research could not be practicably carried out without the waiver.  In order to be 
able to identify a sufficient number of potential participants, while remaining within 
the resources of the project, an automated pre-screening process is necessary. 
ÔÇ∑ There will be no new/timely information discovered by [CONTACT_554698]. 
13) Process to Document Consent in Writing 
Consent will be documented in writing using the standard PPHS consent template.  The 
team will adhere to "SOP HRP-091 Written Documentation of Consent.‚Äù 
 
14) Vulnerable Populations 
As indicated in the table below, vulnerable populations will not be included. 
Include Exclude Vulnerable Population Type  
 X Adults unable to consent  
 X Individuals who are not yet adults (e.g. infants, children, teenagers)  
 X Wards of the State (e.g. foster children)  
 X Pregnant women  
 X Prisoners 
 
15) Multi-Site Human Research (Coordinating Center) 
 
N/A. 
 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
24 
Revised 9/2/14 
16) Community-Based Participatory Research 
N/A. 
17) Sharing of Results with Subjects 
Results that are deemed to be clinically relevant by [CONTACT_978] [INVESTIGATOR_554673].  Permission will also be sought from the participant to share such results with 
their primary care provider. 
18) External IRB Review History 
 
N/A. 
 
19) Control of Drugs, Biologics, or Devices 
 
The Mount Sinai research pharmacy will provide the study drug to the participants. Accountability 
and destruction will also be managed by [CONTACT_56636].   
 
References 
1. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV 
infection. Immunity . 2013;39(4):633-645. 
2. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of 
HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25(11):1385-1394. 
3. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune 
activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371. 
4. Robinson-Papp J, Sharma S, Simpson DM, Morgello S. Autonomic dysfunction is common in HIV and 
associated with distal symmetric polyneuropathy. J Neurovirol . 2013;19(2):172-180.  
5. Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with 
medical morbidity. AIDS Patient Care STDS . 2013;27(10):539-543. 
6. Robinson-Papp J, Elliott KJ, Pi[INVESTIGATOR_554674] M, Morgello S. Autonomic neuropathy in HIV: A case report 
and review of potential symptoms in an advanced-stage, HIV cohort. WJA. 2012;2(3):265-269. 
7. Robinson-Papp J, Sharma S, Dhadwal N, Simpson DM, Morgello S. Optimizing measures of HIV-
associated neuropathy. Muscle Nerve. 2014. 
8. England JD, Gronseth GS, Franklin G, et al. Practice parameter: Evaluation of distal symmetric 
polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). 
report of the american academy of neurology, american association of neuromuscular and 
electrodiagnostic medicine, and american academy of physical medicine and rehabilitation. Neurology . 
2009;72(2):177-184. 
9. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: Clinical 
impact, assessment, diagnosis, and management. Diabetes Metab Res Rev . 2011. 
10. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic 
failure. Mayo Clin Proc. 1993;68(8):748-752. 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
25 
Revised 9/2/[ADDRESS_728560]. Curr Diab Rep . 2006;6(6):417-423. 
12. Thomaides T, Karapanayiotides T, Zoukos Y, et al. Gastric emptying after semi-solid food in multiple 
system atrophy and parkinson disease. J Neurol. 2005;252(9):1055-1059. 
13. Tanaka Y, Kato T, Nishida H, et al. Is there delayed gastric emptying in patients with multiple system 
atrophy? an analysis using the (13)C-acetate breath test. J Neurol. 2012;259(7):1448-1452. 
14. Stacher G, Lenglinger J, Bergmann H, et al. Impaired gastric emptying and altered intragastric meal 
distribution in diabetes mellitus related to autonomic neuropathy? Dig Dis Sci . 2003;48(6):1027-1034. 
15. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: A 
population-based study. Diabetes Care . 2004;27(12):2942-2947. 
16. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The autonomic 
symptom profile: A new instrument to assess autonomic symptoms. Neurology . 1999;52(3):523-528. 
17. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal 
subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest . 1977;59(6):1158-
1166. 
18. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal 
bacterial overgrowth. Scand J Gastroenterol . 1996;31(9):875-880. 
19. Husebye E, Skar V, Hoverstad T, Iversen T, Melby K. Abnormal intestinal motor patterns explain 
enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology . 
1995;109(4):1078-1089. 
20. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in parkinson's 
disease. Mov Disord . 2013;28(9):1241-1249. 
21. George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis 
Sci. 2012. 
22. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use 
are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol 
Ther. 2013;37(11):1103-1111.  
23. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small 
bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. 
Ann Surg . 1998;228(2):188-193. 
24. Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human 
cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol . 2002;97(9):2364-2370. 
25. Wang ZT, Yao YM, Xiao GX, Sheng ZY. Risk factors of development of gut-derived bacterial 
translocation in thermally injured rats. World J Gastroenterol . 2004;10(11):1619-1624. 
26. Batman PA, Miller AR, Sedgwick PM, Griffin GE. Autonomic denervation in jejunal mucosa of 
homosexual men infected with HIV. AIDS. 1991;5(10):1247-1252. 
27. Barnert J, Dumitrascu DL, Wienbeck M. Dyspepsia in AIDS is correlated to ultrasonographic changes 
of antral distension. Eur J Ultrasound . 2000;11(3):189-197. 
28. Konturek JW, Fischer H, van der Voort IR, Domschke W. Disturbed gastric motor activity in patients 
with human immunodeficiency virus infection. Scand J Gastroenterol . 1997;32(3):221-225. 
29. Sharpstone D, Neild P, Crane R, et al. Small intestinal transit, absorption, and permeability in patients 
with AIDS with and without diarrhoea. Gut. 1999;45(1):70-76. 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
26 
Revised 9/2/14 
30. Neild PJ, Nijran KS, Yazaki E, et al. Delayed gastric emptying in human immunodeficiency virus 
infection: Correlation with symptoms, autonomic function, and intestinal motility. Dig Dis Sci . 
2000;45(8):1491-1499. 
31. Tracey KJ. Reflex control of immunity. Nat Rev Immunol . 2009;9(6):418-428.  
32. Watkins LR, Goehler LE, Relton JK, et al. Blockade of interleukin-1 induced hyperthermia by 
[CONTACT_306281]: Evidence for vagal mediation of immune-brain communication. Neurosci 
Lett. 1995;183(1-2):27-31.  
33. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic 
inflammatory response to endotoxin. Nature. 2000;405(6785):458-462. 
34. Peterson CY, Krzyzaniak M, Coimbra R, Chang DC. Vagus nerve and postinjury inflammatory 
response. Arch Surg . 2012;147(1):76-80. 
35. Papaioannou VE, Dragoumanis C, Theodorou V, Gargaretas C, Pneumatikos I. Relation of heart rate 
variability to serum levels of C- reactive protein, interleukin 6, and 10 in patients with sepsis and septic 
shock. J Crit Care. 2009;24(4):625.e1-625.e7. 
36. Tateishi Y, Oda S, Nakamura M, et al. Depressed heart rate variability is associated with high IL-6 
blood level and decline in the blood pressure in septic patients. Shock. 2007;28(5):549-553. 
37. Matteoli G, Gomez-Pi[INVESTIGATOR_554675], Nemethova A, et al. A distinct vagal anti-inflammatory pathway 
modulates intestinal muscularis resident macrophages independent of the spleen. Gut. 2014;63(6):938-
948. 
38. Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune homeostasis. Gut. 
2013;62(8):1214-1222. 
39. Tsoyi K, Jang HJ, Kim JW, et al. Stimulation of alpha7 nicotinic acetylcholine receptor by [CONTACT_554699]-1 induction. Antioxid Redox Signal . 2011;14(11):2057-2070. 
40. Huston JM, Gallowitsch-Puerta M, Ochani M, et al. Transcutaneous vagus nerve stimulation reduces 
serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med . 
2007;35(12):2762-2768. 
41. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential 
regulator of inflammation. Nature. 2003;421(6921):384-388. 
42. Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N. Stimulation of alpha7 
nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human 
monocytes. Shock. 2006;26(4):358-364. 
43. Valdes-Ferrer SI, Crispin JC, Belaunzaran PF, Cantu-Brito CG, Sierra-Madero J, Alcocer-Varela J. 
Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by 
[CONTACT_10840]. AIDS Res Hum Retroviruses . 2009;25(8):749-755. 
44. Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase 
inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62(5):708-715.  
45. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase 
inhibition: A novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg 
Psychiatry. 2003;74(9):1294-1298. 
46. Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine 
for the treatment of orthostatic hypotension in autonomic failure. Hypertension . 2010;56(5):847-851. 
 Protocol Name:  [CONTACT_554700], gastrointestinal motility, and inflammation 
in HIV 
Principal Investigator:  [INVESTIGATOR_554655] -Papp MD, MS  
Primary Contact 
[CONTACT_5627]/Contact [CONTACT_5628]:  Mary Catherine George; [EMAIL_10548] ; 212-
241-0784  
Date Revised:  7/1/2016 
Study Number:  HS#: 15-[ZIP_CODE]/GCO#: 14 -1454(0001) NIH  
 
27 
Revised 9/2/14 
47. Zilliox L, Peltier AC, Wren PA, et al. Assessing autonomic dysfunction in early diabetic neuropathy: 
The survey of autonomic symptoms. Neurology . 2011;76(12):1099-1105. 
48. Novak P. Quantitative autonomic testing. J Vis Exp. 2011;(53). pii: 2502. doi(53):10.3791/2502. 
49. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Absorbable vs. non-absorbable 
antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. 
Aliment Pharmacol Ther . 2005;21(8):985-992. 
50. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying 
scintigraphy: A joint report of the american neurogastroenterology and motility society and the society of 
nuclear medicine. J Nucl Med Technol . 2008;36(1):44-54. 
51. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spi[INVESTIGATOR_240457]. Functional bowel 
disorders. Gastroenterology . 2006;130(5):1480-1491. 
52. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: A refined and abbreviated 
composite autonomic symptom score. Mayo Clin Proc . 2012;87(12):1196-1201. 
53. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the 
medical outcomes study HIV health survey (MOS-HIV). Qual Life Res . 1997;6(6):481-493. 
54. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV 
symptom index. J Clin Epi[INVESTIGATOR_5541] . 2001;[ADDRESS_728561] 1:S77-90. 
  